This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alnylam Presents New Pre-clinical Data On RNAi Therapeutics For Cardiovascular Disease At American Heart Association Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from two RNAi therapeutic programs for cardiovascular disease, including: ALN-PCSsc, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; and ALN-ANG, an RNAi therapeutic targeting ANGPTL3 for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia. These data were presented at the American Heart Association (AHA) Scientific Sessions held November 16 – 20, 2013 in Dallas, Texas. In a presentation titled “ A Subcutaneous Platform for RNAi Therapeutics Targeting Metabolic Diseases: PCSK9 and ANGPTL3,” Alnylam scientists and collaborators presented updated non-human primate (NHP) data showing that subcutaneous administration of ALN-PCSsc led to an up to 95% knockdown of plasma PCSK9 and an up to 67% reduction of low density lipoprotein cholesterol (LDL-C) – in the absence of statin co-administration. In addition, new results were presented for ALN-ANG, showing a greater than 95% reduction of triglycerides and greater than 85% reduction of LDL-C in a rodent model of mixed hyperlipidemia. ALN-PCSsc and ALN-ANG utilize the company’s proprietary GalNAc-siRNA conjugate delivery platform, which is designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor, enabling subcutaneous dose administration with a wide therapeutic index. ALN-PCSsc and ALN-ANG are programs in the company’s “Alnylam 5x15” product development and commercialization strategy, where the company aims to advance at least five RNAi therapeutic programs toward genetically validated disease targets into clinical development, including programs in advanced stages, by the end of 2015.

“Our recent progress with GalNAc-siRNA conjugates enables advancement of subcutaneously administered RNAi therapeutics for the treatment of cardiovascular disease, and our new data presented at the AHA meeting feature our efforts with ALN-PCSsc and ALN-ANG. With ALN-PCSsc, our new study results in non-human primates show an up to 95% knockdown of plasma PCSK9 and an up to 67% reduction of LDL-C – in the absence of statin co-administration, with a very durable knockdown of more than 50 days after the last dose. We believe these results support a highly competitive target product profile, and we look forward to advancing ALN-PCSsc toward clinical trials in 2014 with our partner The Medicines Company,” said Rachel Meyers, Ph.D., Vice President of Research and RNAi Lead Development at Alnylam. “In addition, our scientists presented new data from our discovery program with ALN-ANG. Specifically, a lead GalNAc-siRNA conjugate targeting ANGPTL3 showed a greater than 95% reduction of triglycerides and a greater than 85% reduction of LDL-C in a mouse model of mixed hyperlipidemia. These pre-clinical results phenocopy the human genetics for loss of function in ANGPTL3, and are supportive of our efforts to advance this new RNAi therapeutic program into later stages of pre-clinical development.”

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs